IRWD
Ironwood Pharmaceuticals, Inc.
IRWD offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
LLY
Eli Lilly and Company
LLY has a slight edge over IRWD overall, supported by lower modeled downside and stronger fundamentals.
IRWD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Healthy |
IRWD's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
IRWD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 3.6x | $4.85 | — |
| Cheap | 4x | $3.62 | -25% |
| Current | 5.4x | $4.85 | — |
| Fair | 12x | $10.94 | +125% |
| Expensive | 24x | $21.19 | +337% |
Historical ranges are pointers, not guarantees.
IRWD has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
IRWD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect strong earnings and revenue growth for IRWD, with profitability improving.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
IRWD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.37 | +52% |
| Q3 2026 | $0.90 | +500% |
| Q2 2026 | $0.77 | +$0.83 |
| Q1 2026 | $0.60 | +$0.81 |
| Q4 2025 | $0.13 | +$0.14 |
| Q3 2025 | $0.15 | +$0.18 |
| Q2 2025 | -$0.06 | -250% |
| Q1 2025 | -$0.21 | +$6.58 |
| Q4 2024 | -$0.01 | +$6.50 |
IRWD's earnings per share have fallen from their peak: $0.90 over the past year, against $3.25 in late 2021.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over IRWD on earnings, with more consistent year-over-year improvement.
IRWD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $133M | +9% |
| Q2 2026 | $113M | +33% |
| Q1 2026 | $106.5M | +159% |
| Q4 2025 | $47.7M | -47% |
| Q3 2025 | $122.1M | +33% |
| Q2 2025 | $85.2M | -9.7% |
| Q1 2025 | $41.1M | -45% |
| Q4 2024 | $90.5M | -23% |
IRWD's revenue is growing: $133M last quarter, up 9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 70% | +8.2 points |
| Q2 2026 | 70% | +17 points |
| Q1 2026 | 68% | +139 points |
| Q4 2025 | 14% | -21 points |
| Q3 2025 | 62% | +34 points |
| Q2 2025 | 53% | +27 points |
| Q1 2025 | -71% | -86 points |
| Q4 2024 | 35% | +2.8 points |
IRWD has the edge over LLY on profitability, with a higher operating margin.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over IRWD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
IRWD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | $74.6M | +390% |
| Q3 2025 | $47.6M | +382% |
| Q2 2025 | -$15.1M | -145% |
| Q1 2025 | $19.9M | -56% |
| Q4 2024 | $15.2M | -57% |
| Q3 2024 | $9.9M | -70% |
| Q2 2024 | $33.4M | -4.5% |
| Q1 2024 | $44.9M | -44% |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with IRWD at down 24%.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
IRWD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +998K shares |
| 1 year | -5.4% | -9.6M shares |
| 3 years | -10% | -18.7M shares |
| 5 years | +1.8% | +2.9M shares |
| Available history | +7.8% | +12.2M shares |
IRWD has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
| Q3 2022 | — |
| Q1 2022 | $92.5M |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
IRWD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.9x | Very low |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 0.8x | Very low |
| Q4 2025 | 1.7x | Healthy |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | 1.7x | Healthy |
| Q4 2024 | 3.1x | Elevated |
IRWD has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
IRWD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.6 | Neutral |
| Stochastic | 61.2 | Neutral |
IRWD's weekly RSI is 62 (neutral) and its Stochastic is 61 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
IRWD PE vs Healthcare Sector
| Metric | IRWD | Sector median | Relative |
|---|---|---|---|
| PE | 5.4x | 26x | 79% below |
| PE % | 25 | 29 | 4 pts below |
IRWD has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
IRWD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.91 | 24% above |
| 20 week MA | $4.08 | 19% above |
| 50 week MA | $3.95 | 23% above |
| 100 week MA | $2.81 | 73% above |
| 200 week MA | $5.79 | 16% below |
IRWD has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 16% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over IRWD on trend strength, trading above more of its moving averages.
IRWD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.5 | $11.7 | -13% |
| 2021 | $11.7 | $11.9 | +1.3% |
| 2022 | $11.9 | $12.4 | +4.3% |
| 2023 | $12.4 | $11.4 | -7.6% |
| 2024 | $11.4 | $4.45 | -61% |
| 2025 | $4.45 | $3.20 | -28% |
| 2026 YTD | $3.20 | $4.85 | +52% |
IRWD has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.